Get Updates

FORCE Blog

This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.

Get Involved > HBOC Community > FORCE Blog

| More

FORCE Blog

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 6,864 other subscribers

Archives

Posts Tagged ‘BRCA2’

November 2, 2017

When Breast Cancer Treatment Ends: Thoughts On “Can Breast Cancer Come Back?” XRAYS Review

by Jennifer Hintz Note:  Jennifer’s story was submitted in response to our recent XRAY review published July 2017: Can Breast Cancer Come Back? If you have would like to submit a blog post related to one of our XRAYS articles, please contact medhas@facingourrisk.org. I was thrilled to finally hear the words from my oncologist: “You’ve done … + read more

October 25, 2017

We All Love a Good Book or Movie

Some books and movies make us think.  Some make us laugh or cry. Some are educational and others are just plain fun.  And, then some do all of the above.  Below is a list of personal memoirs, self-help and reference books created to share information and stories of those who have experienced hereditary cancer. You … + read more

May 14, 2017

The Lights of May

Special note: In honor of Mother’s Day 2017, and my son, Beau’s graduation which is next week, I’m recycling this post that I wrote in 2012. This post is as relevant as when I wrote it 5 years ago. I have yet to see a firefly in Tampa but tonight I will look extra hard. … + read more

May 11, 2017

Fueling Patient-Focused Health Care

by Melanie Nix I know a woman who has hereditary breast and ovarian cancer (HBOC) syndrome. She is a triple negative breast cancer survivor. She has a BRCA1 gene mutation and is the fifth generation in her family to have breast cancer. She lost her youngest aunt to ovarian cancer after multiple battles with both … + read more

March 28, 2017

SOLO3: A Clinical Trial Comparing the PARP Inhibitor, Olaparib to Standard Chemotherapy for Platinum-Sensitive Relapsed Ovarian Cancer

by Jordan Dietrich  SOLO3 SOLO3 is an exciting phase III ovarian cancer clinical trial that studies the effectiveness and safety of the PARP inhibitor Olaparib (Lynparza) compared to single-agent standard chemotherapy in women with platinum-sensitive relapsed ovarian cancer with germline BRCA1/2 mutations. The trial is designed to confirm the benefit of Olaparib in this subset of … + read more

March 1, 2017

Making Postmastectomy Decisions: The Right Input is Critical

Note: This is part 3 of a 3-part series related to our recent XRAYS review on Roni Caryn Rabin’s New York Times piece, “‘Going Flat’ After Breast Cancer.” In part 1 of the series, FORCE volunteer, Robin Karlin discusses her decisions after mastectomy, and her feelings post-reconstruction. In part 2, Sue Friedman talks about the affect of … + read more

February 23, 2017

Post-Reconstruction Thoughts on “Going Flat”

Note: This is part 1 of a 3-part series related to our recent XRAYS review on Roni Caryn Rabin’s New York Times piece “‘Going Flat’ After Breast Cancer.” by Robin Karlin Roni Caryn Rabin’s New York Times piece, “‘Going Flat’ After Breast Cancer,” brings much-needed awareness to the option of skipping reconstruction after mastectomies for breast … + read more

February 15, 2017

Guest Blog: Join FORCEs at our 2017 HBOC Conference!

by guest blogger, Jane E. Herman When I boarded the flight for my first trip to Orlando in June 2011, my goal was not to hug Mickey Mouse or visit Cinderella’s Castle. Rather, my destination was the sixth annual Joining FORCEs Conference. Not knowing anyone who would be in attendance, I was – not unexpectedly … + read more

January 31, 2017

MEDIOLA: A Clinical Trial Combining a PARP Inhibitor with an Immunotherapy Drug

By Ding Wang, MD and Catherine Jenovai Immune system and cancer Every day our bodies are exposed to various injuries that may damage our cells. The damaged cells with certain types of genetic defects are tagged as abnormal and removed by our immune system. If something goes wrong and the cells are not removed by … + read more

January 26, 2017

Flawed Research and Reporting on the “Angelina Effect” Could Threaten Access to HBOC Care

by Lisa Schlager, Lisa Rezende, PhD and Sue Friedman “Angeline Effect” Angelina Jolie’s May 2013 New York Times editorial “My Medical Choice,” which detailed her decision to have a double mastectomy because she carries a BRCA1 mutation brought unprecedented attention to hereditary cancer and BRCA genetic testing. This “Angelina Effect” created an avalanche of public … + read more

December 22, 2016

Voices of FORCE: My journey with cancer: from witness to young previvor

by Alexandria Groves My journey “with cancer” began when my mom was diagnosed with breast cancer at the age of 32. I’m the oldest of three daughters: I was seven at the time, Kiersten was five, and Victoria was one. Why did my “journey with cancer” begin back then? Because since then, breast cancer and … + read more

December 6, 2016

What Does the Recent Election Mean For the HBOC Community?

by Lisa Schlager The results of the 2016 election and the pending change in administration have triggered renewed focus on the future of healthcare. FORCE released an official statement on the election’s impact on the HBOC community and I hope to address additional issues here. The hereditary cancer community has good reason to be concerned. … + read more

November 17, 2016

Results from the KNOW MORE Ovarian Cancer Survey: Your Comments

by Sue Friedman FORCE’s KNOW MORE campaign helps women diagnosed with ovarian, fallopian tube, or primary peritoneal cancers make informed decisions about genetic counseling and testing for inherited gene mutations. We launched a survey, which was completed by over 1,600 women with ovarian cancer. This blog continues our series on the survey results. We received over … + read more

November 14, 2016

Voices of FORCE: A BRCA Mutation is a Factor in Pancreatic Cancer

By Rona Greenberg Hereditary breast and ovarian cancer is part of my family history. My grandmother, Rebecca, for whom I am named, died from breast/ovarian cancer in1934; my mother was ten years old. My mother died from the same cancer in 1967; I was nineteen years old with three younger sisters. In 1997, I was … + read more

November 1, 2016

Learn About Hereditary Pancreatic Cancer

by Lisa Rezende, PhD November is Pancreatic Cancer Awareness Month. FORCE wants to raise awareness of the risk of pancreatic cancer in the hereditary cancer community. Pancreatic cancer is rare but BRCA carriers have a high risk, up to 5% compared to the 1.5% for the general population. Between BRCA carriers, the risk is higher … + read more

Connect with others.

Call our Helpline

Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.

Join a Local Group

FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.

FORCE:Facing Our Risk of Cancer Empowered